TrialsgrambetaRCTs are beautiful

EUCLID

2017

Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease

In 13,885 patients with symptomatic peripheral artery disease, ticagrelor monotherapy did not reduce cardiovascular death, myocardial infarction or ischaemic stroke compared with clopidogrel monotherapy.

Result

Efficacy: Composite of CV death, MI or ischaemic strokeHR 1.02 (95% CI 0.92-1.13) · P = 0.65

Below 1 favours ticagrelor monotherapy, above 1 favours clopidogrel monotherapy.

Event rates
Absolute difference
0.2 points

The absolute difference is derived from the event rates.

Also reported: Acute limb ischaemia and major bleeding 1.7 % and 1.6 % in both arms.

Original publication
Subtopic
Antithrombotic therapy
Design
Double-blind, event-driven RCT
Relevance
Important: one of several pillars.
Source
Hiatt WR, Fowkes FG, et al. N Engl J Med. 2017;376(1):32-40.doi 10.1056/NEJMoa1611688

Discussion & critique

A clean, fully powered null result with no aspirin arm, so it cannot address antiplatelet choice beyond the two drugs tested. Its value is negative evidence: escalating single-antiplatelet potency buys nothing in PAD, and clopidogrel remains the reference monotherapy.